|Day Low/High||333.66 / 340.70|
|52 Wk Low/High||249.17 / 388.67|
I think M&A activity will pick up markedly going forward across the industry.
Biogen (Nasdaq: BIIB) today announced new findings detailing the benefits that SPINRAZA ® (nusinersen) demonstrates for both infantile- and later-onset spinal muscular atrophy (SMA) populations, including improvement in motor function as well as...
Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) announced today they have expanded their strategic collaboration through a new ten-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological...
Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.
The company will not need to worry about Biogen and Samsung Bioepis launching a biosimilar to challenge the reign of its blockbuster arthritis drug until 2023 after the three companies settled patent actions.
Biogen Inc. (Nasdaq: BIIB) and its partner Samsung Bioepis announced today an agreement with AbbVie (NYSE: ABBV) for the commercialization of IMRALDI, a biosimilar referencing HUMIRA® (adalimumab).
Biogen Inc. (NASDAQ:BIIB) today announced it will report first quarter 2018 financial results on Tuesday, April 24, 2018, before the financial markets open.
Charts are signalling more trouble ahead for the stock.
Pfizer's CEO Ian Read could make almost $28 million in the next year to keep him from retiring. Strangely enough, he may earn it given the healthcare and political environment.
Biogen (Nasdaq: BIIB) will present data from its portfolio of investigational therapies for people with neurodegenerative diseases at the Advances in Alzheimer's and Parkinson's Therapies (AAT-AD/PD) Focus Meeting in...
Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Advances in Alzheimer's and Parkinson's Therapies, an AAT-AD/PD Focus Meeting.
Biogen (Nasdaq: BIIB) today announced new interim Phase 2 results from NURTURE, the ongoing open-label, single-arm study evaluating the efficacy and safety of SPINRAZA ® (nusinersen) among pre-symptomatic...
Biogen Inc. (Nasdaq: BIIB) announced today an agreement to acquire from Pfizer Inc.
TPX, WR, GOV, BIIB and SRE were all recently were downgraded by TheStreet's Quant Ratings service.
Worry abounds on Wall Street this week. Do you know which stocks have the lowest exposure to developments from Washington?
Biogen (Nasdaq:BIIB) and AbbVie (NYSE:ABBV) today announced the voluntary worldwide withdrawal of ZINBRYTA for relapsing multiple sclerosis.
Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Cowen and Company 38 th Annual Health Care Conference.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AC, BJRI, SUN, UNT Downgrades: AAC, BELFA, BIIB, BMCH, EIX, GXP, KMX, LAWS, LUK, MUX, RPXC, TPX, VDSI, WR Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc.
While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.
Biogen (Nasdaq: BIIB) announced today that in the Phase 2b dose-ranging ACTION 2 study in individuals with acute ischemic stroke (AIS), natalizumab did not demonstrate improvement in clinical outcomes compared to placebo.
Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Leerink Partners 7th Annual Global Healthcare Conference.
Jim Cramer explains how to rely on long-term themes to take advantage of this market's wild action.
The biotech sector has seen a big rally, but there are still opportunities.
The challenge of this market is to keep finding new buy entries as more and more stocks become extended.
Here's what you need to know now for Thursday, Jan. 25
Stocks come off early highs after Caterpillar shares trade lower.
U.S. stock futures rise as the dollar plunges to a fresh three-year low. Caterpillar, Intel and 3M leading the earnings calendar.
Biogen Inc. (Nasdaq: BIIB) today reported full year and fourth quarter 2017 financial results, including: Full year total revenues of $12.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.